Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET • Anticipates Reporting Topline Data from EDP-323 Respiratory Syncytial Virus (RSV) Challenge Study in Q3 2024 and Phase 2 Study of Zelicapavir in Pediatric RSV Patients in 2H 2024 • Selection of Chronic Spontaneous Urticaria (CSU) Development Candidate Targeted for Q4 2024 • Operations Supported by Cash and Marketable Securities Totaling $300.3 Million at March ...